Integral Diagnostics (IDX) investor relations material

Executive summary

• Revenue grew 55.6% year-over-year to AUD 393.5 million for 1H FY26, driven by the Capitol merger/acquisition and organic growth.

• Operating EBITDA increased 75.6% to AUD 81.1 million, with margin improving to 20.6% (up 230bps year-over-year).

• Operating NPAT rose 154% to AUD 22.3 million; Operating diluted EPS up 66.2% to 5.9 cps.

• Interim dividend per share increased 32% to 3.3 cps, with a payout ratio of 55.2% of Operating NPAT.

• Capitol merger synergies exceeded expectations, delivering over AUD 14 million in annualised savings.

Financial highlights

• Revenue up 55.6% YoY to AUD 393.5 million, including Capitol's six-month contribution.

• Operating EBITDA up 75.6% to AUD 81.1 million; margin at 20.6%.

• Operating NPAT up 154% to AUD 22.3 million.

• Operating free cash flow increased nearly 65% YoY to AUD 35.8 million.

• Net debt to EBITDA reduced to 2.5x from 2.8x YoY.

Outlook and guidance

• FY26 operating EBITDA margin forecast around 21%, driven by new site ramp-ups and procurement efficiencies.

• Revenue growth expected to continue, supported by government initiatives and further margin expansion.

• Group CapEx for FY26 expected between AUD 45 million and AUD 55 million.

• Net debt to EBITDA projected to trend down further, maintaining target ratio of 2.5x or less.

• Focus on organic earnings growth, radiologist recruitment, operational efficiency, and digital/AI adoption.